Targeting autophagy to sensitive glioma to temozolomide treatment

Yuanliang Yan¹,², Zhijie Xu³, Shuang Dai¹,², Long Qian¹,², Lunquan Sun⁴ and Zhicheng Gong¹,²*

Abstract
Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent high-grade gliomas. However, the efficacy of TMZ is often limited by the development of resistance. Recently, studies have found that TMZ treatment could induce autophagy, which contributes to therapy resistance in glioma. To enhance the benefit of TMZ in the treatment of glioblastomas, effective combination strategies are needed to sensitize glioblastoma cells to TMZ. In this regard, as autophagy could promote cell survival or autophagic cell death, modulating autophagy using a pharmacological inhibitor, such as chloroquine, or an inducer, such as rapamycin, has received considerably more attention. To understand the effectiveness of regulating autophagy in glioblastoma treatment, this review summarizes reports on glioblastoma treatments with TMZ and autophagic modulators from in vitro and in vivo studies, as well as clinical trials. Additionally, we discuss the possibility of using autophagy regulatory compounds that can sensitive TMZ treatment as a chemotherapy for glioma treatment.

Keywords: glioblastoma, temozolomide, treatment resistance, autophagy

Background
Glioblastoma or glioblastoma multiform (GBM) is an aggressive astrocytic cell neoplasm and one of the leading causes of cancer-related deaths in both pediatric and adult populations. The median survival of patients with GBM is approximately 12–15 months after the initial diagnosis. Conventional therapies for patients with newly diagnosed GBM include surgical tumor resection followed by radiation therapy and chemotherapy. Though these therapeutic methods have increased the survival rate to 14.6 months, the survival advantages are only palliative [1, 2]. In March 2005, the U.S. Food and Drug Administration approved temozolomide (TMZ) concomitantly with radiotherapy for the treatment of adults with newly diagnosed glioblastoma as well as using TMZ alone as a maintenance treatment [3]. To date, TMZ is the most widely used and effective first-line chemotherapeutic drug for glioblastoma patients [4, 5], although several chemotherapeutic agents can be found on the current pharmaceutical market [3].

Autophagy is activated in tumor cells by chemotherapeutic agents and radiation [6, 7], and the process constitutes a potential target for cancer therapy. Since autophagy was discovered, it has been thought to act as a pro-survival or pro-death response to several stresses, especially chemotherapy and radiotherapy, at the cellular and organic levels [8]. The mechanism by which autophagy could perform these seemingly opposite roles remained elusive until recently. Under moderate stimulus conditions, the autophagic pathway operates to supply cells with metabolic substrate, contributing to the maintenance of cell survive [9]. However, a considerable body of literature reports that uncontrolled autophagy is also a cell death mechanism that can occur either in the absence of detectable signs of apoptosis or concomitantly with apoptosis [10]. Similarly, using C. elegans as a model system, Kang C et al. found that physiological levels of autophagy promote optimal survival of C. elegans upon stresses, whereas either insufficient or excessive levels of autophagy are pro-death [11]. In addition, for a multicellular organism, autophagic cell death might well represent another pro-survival mechanism, which provides metabolic supplies during whole-body nutrient deprivation via the heterophagy [9].

* Correspondence: gongzhicheng2013@163.com
¹Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China
²Institute of Hospital Pharmacy, Central South University, Changsha 410008, China
Full list of author information is available at the end of the article

© 2016 Yan et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
As the dual roles of autophagy in the response to chemoradiotherapy, the modulation of autophagy in response to therapeutics could have anti-cancer efficacy as well as help with therapy resistance [6]. In some cases, autophagy-delayed apoptotic death (type I programmed cell-death) in cancer cells undergoing therapeutic treatment; the treatment of these cells with autophagy inhibitors, such as chloroquine (CQ); or the knockdown of autophagy genes, including Beclin1 and other ATG genes, enhanced therapy-induced apoptosis [12]. Autophagy also contributes to promote cell survival [13], and blocking the autophagic process increases the efficacy of a variety of anti-cancer agents [14]. However, according to other studies, various therapeutic methods could enhance autophagic cell death (type II programmed cell-death) in glioblastomas [15], hepatocellular carcinoma [16], etc. Thus, the potential clinical applications for the monitoring of autophagy in gliomas and other cancers require the detection of current therapeutic effects and the development of novel anticancer strategies. These treatment strategies include the induction of autophagy to enhance its antitumor effects and the inhibition of autophagy to induce apoptosis [17].

In GBM, TMZ-induced autophagy is putative mechanism of TMZ action in cancer cells and patients [6, 18]. It has been proposed that autophagy could lead to either cancer cell survival or cell death, depending on the cellular context [19, 20]. On one hand, TMZ-induced autophagy seems to have a cytoprotective role. Lenz G’s group demonstrated that acute treatment with TMZ induces the sustained inhibition of Akt-mTOR (the mechanistic target of rapamycin (serine/threonine kinase)), which produced a transient induction of autophagy, leading to cell resistance of the therapy [21]. On the other hand, Gao S et al. found that the cytotoxicity of TMZ to glioma cells was enhanced by autophagy when combined with thalidomide, a drug proposed to affect the PI3K (phosphatidyl inositol 3 kinase) /Akt/mTOR pathway, which plays a role in autophagy regulation [22]. Accordingly, autophagic cell death was found to be necessary for the antitumor effects of the combination of TMZ and radiotherapy [23]. These data are compatible with the theory that autophagy is mostly a survival process, whereas mortal autophagic flux most easily achieved by a combination treatment can be exploited in anticancer therapy. To understand the effectiveness of regulating autophagy in glioblastoma treatment, this review focuses on reports on glioblastomas treated with TMZ and autophagic modulators from in vitro and in vivo studies, as well as clinical trials.

**Known resistance mechanisms of TMZ**

TMZ is a small lipophilic molecule (194 Da) and an orally available imidazotetrazine-class alkylating agent [24]. The cytotoxicity of TMZ is thought to result from the formation of O\(^6\)-methylguanine (O\(^6\)MeG) in DNA, which mispairs with thymine during DNA replication, triggering futile cycles of the mismatch repair system and resulting in subsequent DNA damage [25]. Due to its ease of administration, tolerability, and known capacity to cross the blood–brain barrier, TMZ provides modest antitumor activity and is currently used to treat glioblastomas. In addition, fibrin glue (FG), a drug delivery system, can effectively administer TMZ directly to the target tumor and exert antitumor effects, with no severe damage to the normal brain tissue [26]. TMZ is considered the most effective drug for the treatment of GBM. However, overtime, GBM cells become resistant to the cytotoxicity caused by TMZ. This resistance is related to the implementation of several mechanisms, discussed below (Fig 1).

One of the well-documented mechanisms in GBM resistance involves O\(^6\)MeG DNA methyltransferase (MGMT). MGMT can eliminate the TMZ-induced DNA damage by removing the methyl group in the O-6 position of the substrate guanine, further generating TMZ resistance [27]. Additionally, as the level of MGMT is inversely related to the density of cytosine phosphate guanine (CpG) methylation in CpG islands, the decreased methylation of the MGMT promoter improves survival after TMZ chemotherapy [28]. To date, therapeutic molecules inhibiting MGMT, such as O\(^6\)-(4-bromo-methenyl) guanine and O\(^6\)-benzyl guanine, have been used in clinical trials preceding treatment with TMZ.

DNA mismatch repair (MMR) [29] and base excision repair (BER) [30] are the primary DNA repair systems involved in TMZ resistance mechanisms. The MMR system can correct nucleotide base mismatches generated during DNA synthesis. When MGMT is reduced or absent, the existence of O\(^6\)MeG can be recognized by MMR protein complexes and paired with thymine to form O\(^6\)MeG/T. The futile cycles of the insertion and excision of thymine mentioned above lead to cell cycle arrest and apoptosis. Conversely, the impairment of the MMR pathway causes a failure in the ability to recognize O\(^6\)MeG/T, resulting in less effective TMZ treatment. The BER system participates in the repair of DNA damage caused by alkylating agents. TMZ is thought to form N3 and N7 methylations in DNA, which is lethal if not repaired. BER can repair N3 lesions, giving rise to a TMZ resistant phenotype.

Apart from DNA repair systems, it has been demonstrated that other factors, including epidermal growth factor receptor (EGFR) [31], phosphatase and tensin homolog (PTEN) [32], galectin-1 [33], murine double minute 2 (Mdm2) [34], p53 [35], PI3K/AKT/mTOR pathway [36], and sphingosine-1-phosphate/ sphingosine kinases [37], play important roles in TMZ resistance.
addition, another recent study showed TMZ-resistant glioblastoma stem cells (GSCs) had enriched MGMT promoter methylation, suggesting intrinsic or rapidly acquired resistance, in which the details of the specific mechanism are still unclear [38]. Although the above mechanisms by which GBM cells become resistant to anticancer drugs has been elucidated, autophagy, an important evolutionarily conserved catabolic process, is now emerging as a crucial player in TMZ resistance. Autophagy can be viewed as having a controversial pro-death or pro-survival role in response to TMZ treatment (Fig 2).

**Effect of autophagy modulation on the TMZ anti-glioblastoma activity**

**Autophagy as a cytoprotective role**

TMZ is considered the most effective drug in the treatment for GBM. However, its efficacy is often limited by tumor recurrence and the development of resistance to TMZ. Autophagy, upon TMZ treatment, mostly functions as a survival mechanism, as its inhibition greatly ameliorates the level of apoptosis following TMZ treatment at therapeutically relevant doses (≤100 μM), suggesting that the inhibition of autophagy may ameliorate the therapeutic outcome of TMZ-based cancer therapy [39, 40] (Tables 1 and 2). Therapeutic molecules inhibiting autophagy, such as CQ and its analogs, have been used in clinical trials preceding treatment with TMZ [41]. Furthermore, the autophagy suppressing functions of Ataxia-telangiectasia mutated (ATM) kinase inhibitors and plant-derived compounds, such as resveratrol, have been demonstrated, including the reduction of tumor volumes and the prolonged survival in mouse xenograft [42, 43]. Autophagy is the process in which damaged or unwanted cytoplasmic constituents are segregated into autophagosomes and designated for lysosomal degradation. Autophagy has a cytoprotective role mainly through eliminating intracellular pathogens via the activation of the innate and adaptive immune responses, and it is also noted for its role in maintaining endoplasmic reticulum (ER) and metabolic homeostasis in tumor cells undergoing chronic hypoxia and nutrient depletion.

**Chloroquine and its analogs**

CQ and its close quinoline-based analogues were developed primarily to treat malaria [44]. However, they are increasingly recognized for their effectiveness in a myriad of non-malarial diseases [45]. They have been shown to have antagonistic effects in late autophagy by controlling acidic lysosomes, and they currently have established roles in the treatment of different cancers, including glioblastoma [46]. With the aim of determining the molecular mechanisms of enhancing the chemotherapeutic effect of CQ on malignant glioblastomas, recent studies have been dedicated to probing the cytotoxicity of CQ combined with TMZ. Reactive oxygen species (ROS) are one of the main
causes of dysfunctional or damaged mitochondria. Hori YS et al. found that CQ increases cellular ROS and augments TMZ cytotoxicity in glioma cells by inhibiting mitochondrial autophagy. The knockdown of Beclin1 by siRNA mimics the ROS-mediated enhancement of cell death induced by CQ [47]. TMZ treatment results in G2/M phase arrest, although apoptosis occurs in a few of the treated glioma cells. CQ could potentiate the chemosensitivity of glioma cells to TMZ via blocking autophagy, which is dependent on the status of p53 [35]. TMZ combined with CQ synergistically inhibits cell growth through G2/M arrest in glioma cells expressing mutant p53, while in cells expressing wild type p53, the combination therapy induces cell death via apoptosis. A previous study established that CQ enhances TMZ cytotoxicity in gliomas by blocking the ER chaperone and cell survival protein GRP78/BiP-dependent autophagy and inducing the expression of CHOP/GADD-153 (an ER stress proapoptotic protein) and PARP (an apoptotic marker) [48]. Furthermore, similar results have been obtained for other quinoline-based antimalarial (QBA) drugs, such as hydroxychloroquine (HCQ), quinine (QN), mefloquine (MFQ), and quinacrine (QN). The order of the inhibition potency of QBAs on autophagy is as follows: QNX > MFQ > HCQ > CQ > QN. In addition, the antitumor activity of the most potent compound, QNX, could selectively accumulate in tumor cell vacuoles in vivo [49].

Targeting autophagy by CQ has attracted attention as an adjuvant therapy for glioblastoma patients (ClinicalTrials.gov Identifier: NCT00486603, NCT02378532, NCT01430351. http://clinicaltrials.gov) (Table 3), because Briceño E et al. reported the efficacy of adding CQ to conventional treatment in a prospective controlled randomized trial [50]. As CQ has a strong antimutagenic effect and a good toxicological profile, the chronic administration of CQ greatly enhanced the response of GBM to antineoplastic treatment [50, 51]. Moreover, the combination of the CQ-analogue HCQ and TMZ significantly increases the number of therapy-associated autophagic vacuoles in the peripheral blood mononuclear cells of glioblastoma patients but with a dose-limiting toxicity [18]. Taken together, these reports suggest that CQ is likely to be beneficial for the treatment of gliomas and holds promise as an effective adjuvant therapy in glioma patients. However, with some limitations, such as differences in pretreatment characteristics and conventional treatment regimens, larger trials are warranted to further confirm the benefit of CQ and CQ-analogs.

As the anti-tumor mechanism of CQ, autophagy inhibition has attracted much more attention to potentiate TMZ cytotoxicity. The combination of TMZ and CQ-analogs is an efficient alternative strategy in glioma treatment and could improve with clinical development. The application of an optimal dose of CQ and TMZ and the treatment schedule are important for the synergistic...
| Cell lines | Therapeutic methods (concentration/exposure time) | Major findings | Interpretation | Reference |
|------------|--------------------------------------------------|---------------|---------------|-----------|
| Rat C6 cells | TMZ 100–1,000 μM/24 hours | CQ potentiated TMZ-induced cytotoxicity. | CQ increased cellular ROS in glioma cells by inhibiting mitochondrial autophagy. | [35] |
| Human U87 cells | CQ 10 μM/24 hours | | | |
| Human LN229, U251, and U87 cells | TMZ 20–100 μM/48 hours | CQ increased the chemosensitivity of glioma cells to TMZ. | | [48] |
| Human GBM8901 cells | TMZ 100 μM/24 hours | Chrysin induced apoptosis, suppressed migration and invasion, and sensitized GBM cells to TMZ. | | [75] |
| Human U87, GBM8401 and GBM-5SH cells | TMZ 400 μM/72 hours | Resveratrol enhanced the therapeutic effect of TMZ against malignant glioma. | Coadministration of resveratrol and TMZ reduced tumor volumes by suppressing ROS/ERK-mediated autophagy. | [42] |
| Human U87, U251 and SHG-44U87 cells | TMZ 100 μM/72 hours | ATM inhibitor ku-55933 enhanced TMZ cytotoxicity in inherently TMZ-sensitive glioma cells. | Ku-55933 inhibited the phosphorylation of AMPK, and reduced the levels of TMZ-induced autophagy. | [54] |
| Human U87 and U251 cells | TMZ 100 μM/72 hours | TMZ chemoresistance was overwhelmed by targeting ATM. | Ku-55933 inhibited the activation of ULK1 and interrupted the cytoprotective process of autophagy. | [55] |
| Human U-118 cells | TMZ 0–500 μM/24/48 hours | Inhibition of ERK1/2 partially eradicated the chemoresistance of U-118 GBM cells to TMZ. | ERK1/2 specific inhibitors U-0126 prevented the activation of autophagy by TMZ. | [19] |
| Human U87 cells | U-0126 15 mM/48 hours | | | |
| Human LN229 and U251 cells | TMZ 100 μM/24 hours | Targeting eEF-2 kinase can enhance the anti-glioma activity of TMZ. | Inhibition of eEF-2 kinase by siRNA or NH125 blocked the activation of TMZ-induced autophagy. | [65] |
| Human U251 cells | eEF-2 SiRNA N/A | | | |
| Human U87 cells | TMZ 200 and 400 μM/72 hours | Targeting eEF-2 kinase can enhance the anti-glioma activity of TMZ. | Autophagy inhibition sensitizes TMZ and curcumin treated cells to apoptosis. | [81] |
| Human LN229 and U251 cells | Curcumin 15 μM/72 hours | | | |
| Human U87 cells | 3-MA 4 mM/72 hours | | | |
| Human U87 cells | TMZ 400 μM/36-72 hours | TMZ induced autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. | ETC inhibitors rotenone, sodium azide, oligomycin, or ER stress inhibitor 4-PBA reduced autophagy and consequently increased TMZ-induced apoptosis. | [61] |
| Human U87 cells | rotenone 20 nM/1 hour | | | |
| Human U87 cells | sodium azide 150 μM/1 hour | | | |
| Human U87 cells | oligomycin 1 nM/1 hour | | | |
effect of the combination of the drugs. However, the detailed mechanistic role of CQ-analogs and their derivations as an enhancer of TMZ needs to be further examined.

### Kinase inhibitors

A recent study has found through database mining and mutation analysis, that approximately 34 kinase genes are mutationally activated at considerable frequencies in glioblastomas [52], indicating that kinase inhibition studies could offer new opportunities for the rational development of therapeutic approaches for glioblastomas.

ATM kinase forms a central node in the DNA damage response phosphorylation cascade by contributing to the initiation, amplification and transmission of the DNA damage signal to downstream substrates [53]. A study by Wang W’s group demonstrated that, in glioblastomas, TMZ treatment induces cytoprotective autophagy through the ATM-AMPK (adenosine monophosphate-activated protein kinase) pathways, which occurs in a MMR protein-MLH1-dependent manner. The ATM inhibitor ku-55933 can abrogate the ATM-AMPK signaling pathway, which further enhances TMZ cytotoxicity in glioma cells [54]. Meanwhile, the interruption of the ATM-AMPK pathways ku-55933 inhibits the cytoprotective process of autophagy, which results in the augmentation of the TMZ cytotoxic effect and promotes glioma cell death under apoptotic stress [55]. In addition, Nadkarni A et al. found the inhibition of ATM activation by ku-55933 suppresses the repair of TMZ-induced DSBs (DNA double-stranded breaks) in inherently TMZ-sensitive tumor lines [56]. The loss of ATM-mediated BER results in increased alkylating agent-induced cytotoxicity in vitro and prolonged survival in xenografts by reducing tumor volumes [57].

The induction of autophagy by TMZ has been shown to result in apoptosis through the activation of the ATM-AMPK (adenosine monophosphate-activated protein kinase) pathways, which occurs in a MMR protein-MLH1-dependent manner. The ATM inhibitor ku-55933 can abrogate the ATM-AMPK signaling pathway, which further enhances TMZ cytotoxicity in glioma cells [54]. Meanwhile, the interruption of the ATM-AMPK pathways ku-55933 inhibits the cytoprotective process of autophagy, which results in the augmentation of the TMZ cytotoxic effect and promotes glioma cell death under apoptotic stress [55]. In addition, Nadkarni A et al. found the inhibition of ATM activation by ku-55933 suppresses the repair of TMZ-induced DSBs (DNA double-stranded breaks) in inherently TMZ-sensitive tumor lines [56]. The loss of ATM-mediated BER results in increased alkylating agent-induced cytotoxicity in vitro and prolonged survival in xenografts by reducing tumor volumes [57].

### Table 1 In vitro studies of autophagy inhibitors on the TMZ anti-glioblastoma activity (Continued)

| Subject | Agent regimen | Major findings | Interpretation | Reference |
|---------|---------------|----------------|----------------|-----------|
| Human U87 and U251 cells | 4-PBA 10mM/1 hour | Targeting VAMP8 alleviated TMZ resistance in glioma cells. | silencing of VAMP8 by SiRNA could impair the TMZ-induced autophagic flux. | [69] |

### Table 2 In vivo studies of autophagy inhibitors and inducers on the TMZ anti-glioblastoma activity

| Effect of autophagy modulation | Subject | Agent regimen | Major findings | Interpretation | Reference |
|-------------------------------|---------|---------------|----------------|----------------|-----------|
| cytoprotective role           | Xenografts of human U87 MG GBM cells in male athymic nu/nu mice | CQ 10 mg/kg + TMZ 5 mg/kg given by oral gavage for 48 hours with water. | CQ enhances the cytotoxic effects of TMZ by blocking autophagy. | CQ in combination with TMZ significantly increased the amounts of LC3B-II, CHOP/GADD-153, and cleaved PARP. | [48] |
|                               | Xenografts of human U87 GBM cells in athymic nude mice | 50 mg/kg of QNX for 24 hours; 25 mg/kg QN, CQ, MFQ, or QNX for 48 hours. | QBAs, a novel class of autophagy inhibitors, are holding the promise for the coadministration treatment of gliomas. | QNX selectively accumulates in tumor cell vacuoles. QBAs have the ability to induce ER stress potentially leading to apoptosis. | [49] |
|                               | Xenografts of human U87 MG GBM cells in nude mice | Resveratrol 12.5 mg/kg + TMZ 10 mg/kg injected intraperitoneally for 12 days. | Resveratrol increases the effect of TMZ in glioma xenografts by reducing tumor volumes. | Coadministration of resveratrol and TMZ suppressing ROS/ERK-mediated autophagy and subsequently inducing apoptosis | [42] |
|                               | Xenografts of SJG2 pediatric GBM in NOD-SCID mice | MA 100 mg/kg + TMZ 65 mg/kg given by oral gavage for two weeks. | Combination had a significant increase in survival. | ATM-MPG axis will lead to improved treatment of alkylating agent-resistant tumors. | [43] |
| Autophagy-associated cell death| Xenografts of human U87 and T98 GBM cells in nude mice | THC 15 mg/kg + TMZ 5 mg/kg injected intraperitoneally for 14 days in 100 mL of PBS supplemented with 5 mg/mL defatted and dialyzed BSA. | Combined treatment with THC and TMZ strongly reduces the growth of glioma xenografts. | Combined treatment with THC and TMZ enhances autophagy-mediated cell death. | [86] |
|                               | Xenografts of human U87 MG GBM cells in female BALB/c nu/nu mice | AdWT or CRAd-S-pk7 3x10^6 vp in 5 μl + TMZ 70 or 10 mg/kg in 100 μl injected with five consecutive intraperitoneal. | In which 90% of the mice with intracranial tumours were long-term survivors after treatment with TMZ and CRAd-S-pk7. | As both LC3 and cleaved Caspase-3 expressed, both autophagy and apoptosis are responsible for cell death. | [90] |
vivo [43]. These results suggest that ku-55933 may be an effective TMZ-sensitizing agent.

The mitogen-activated protein kinase (MAPK) signaling pathway is usually activated by upstream genomic events and functions as a tumor suppressor and more commonly, a pro-oncogenic signal [57]. Therapies targeted toward MAPK/extracellular signal-regulated kinase (ERK) components have various response rates when used in different solid tumors, such as glioblastomas [58]. Previous studies have reported that in patient tumor tissue samples, ERK was phosphorylated, indicating that this survival pathway was active in glioma cells [59]. Lin CJ et al. revealed that TMZ induces the generation of ROS and the activation of ERK, which consequently leads to protective autophagy in glioma cells [42]. Because ERK signaling pathways sustain key features that characterize gliomas, i.e., enhanced proliferation and invasion, protection from proapoptotic stimuli and the activation of autophagy, it is likely that they may contribute to TMZ chemoresistance. The results from Lopes MC’s group demonstrated that the chemoresistance of U-118 GBM cells to TMZ was partially eradicated when the cells were simultaneously treated with TMZ and specific inhibitors of the ERK1/2 kinase signaling pathways [19]. In addition, the MAPK/c-Jun N-terminal kinase (JNK) signaling transduction pathway functions to induce defense mechanisms that protect organisms against various stress situations. This pathway has also been repeatedly linked to the molecular events involved in autophagy regulation [60]. Lin CJ et al. reported that TMZ-induced autophagy was mediated by JNK activation in U87 cell lines, and the JNK inhibitor, SP600125, inhibited cell autophagy, furtherly increasing the percentage of cells undergoing apoptosis [61].

Eukaryotic elongation factor-2 kinase (eEF-2 kinase, also known as calmodulin-dependent protein kinase III), a critical enzyme controlling protein translation, is up-regulated in several types of malignancies, including gliomas [62]. Studies have reported that the expression and activity of eEF-2 kinase favor glioma cell survival and by blunting the autophagic response, eEF-2 kinase modulates the sensitivity of tumor cells to therapeutic agents, such as curcumin [63] and MK-2206 [64]. Liu XY et al. found that inhibiting eEF-2 kinase with siRNA or the inhibitor 1-Hexadecyl-2-methyl-3-(phenylmethyl)-1H-imidazo[4,5-b]pyridine (NH125) could enhance the anti-glioma activity of TMZ, and this sensitizing effect was associated with the blockade of autophagy and the augmentation of apoptosis caused by TMZ [65].

**Mitochondrial electron transport chain inhibitors**

Autophagy is a crucial process for cells to maintain homeostasis and survival through the degradation of cellular proteins and organelles, including mitochondria and ER [66]. Studies have indicated that TMZ could induce ROS/ERK-mediated cytoprotective autophagy to

| Table 3 Clinical trials of CQ-analogs combined with TMZ in cancer therapy |
|----------------|-------|-----------------|-----------------|----------------|-----------------|-----------------|
| Study          | Type  | Year of registration | Sponsor                              | Drugs                                      | Tumor type   | Targeted enrolment | Status     | Major findings                                      |
| NCT00486603[41] | Phase I | 2007           | Sidney Kimmel Comprehensive Cancer Center | 200, 400, 800 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT | Newly diagnosed GBM | 16               | Complished     | HCQ 600 mg/day was found to be the MTD in this combination. |
| NCT00486603[41] | Phase II | 2007          | Sidney Kimmel Comprehensive Cancer Center | 600 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT | Newly diagnosed GBM | 76               | Complished     | Median survival of 15.6 mos with survival rates at 12, 18, and 24 mo of 70%, 36%, and 29%. PK analysis indicated dose-proportional exposure for HCQ. AV in PBMC patients with Cmax above 1785 ng/mL had an increased median AV change of 1.01. |
| NCT02378532# | Phase I | 2015           | Maastricht Radiation Oncology | 200-600 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT | Newly diagnosed GBM | 9                | Not yet open   | N/A                                                      |
| NCT01430351# | Phase I | 2011           | M.D. Anderson Cancer Center | 250 mg/day MFQ for 3 d/week+ 150 mg/m2/day TMZ for 5 d [q4wk] | Post-RT Glioblastoma | 144              | Recruiting participants | N/A                                                      |

# Further information can be found at http://clinicaltrials.gov
protect the glioma cells from apoptosis [42, 61]. When treating the glioma cells with a combination of TMZ and mitochondrial electron transport chain inhibitors, such as rotenone, sodium azide, oligomycin or the ER stress inhibitor 4-phenylbutyrate, the TMZ-induced apoptosis and cell death could be significantly augmented by inhibiting autophagy [61].

**Vesicle-associated membrane protein 8 siRNA**
Soluble N-ethylmaleimide-sensitive factor receptors (SNAREs) are a superfamily of small proteins with more than 35 members in mammals, varying in size and primary structure. As an essential mechanism for cellular activities, SNAREs have been observed in the progression of various tumors [67, 68]. Vesicle-associated membrane protein 8 (VAMP8), first identified as an endosomal SNARE, is significantly overexpressed in human glioma specimens and promotes cell proliferation. Furthermore, VAMP8 contributes to TMZ resistance by elevating the autophagic level, while silencing of VAMP8 using siRNA could impair the autophagic flux and alleviate TMZ resistance in glioma cells [69].

**Isocitrate dehydrogenase 1 mutation**
Genetic and epigenetic studies, such as the Cancer Genome Atlas Project (TCGA), are finding enormous heterogeneity in the mutations and other genetic aberrations among GBM patients [70]. Isocitrate dehydrogenase 1 (IDH1) is a potential biomarker and drug target for GBM. Mutations of IDH1 are one of the most common and earliest detectable genetic alterations in low-grade diffuse gliomas, and evidence supports this mutation as a driver of gliomagenesis [71]. Among these mutations, the R132H mutation seems to be a more powerful prognostic marker in slow-growing gliomas, and it is associated with a more favorable outcome and better response to TMZ [72]. Gilbert MR et al. recently reported that the autophagy substrate p62/sequestosome-1 protein accumulates in both U87 cells that overexpress the R132H mutant protein and patient-derived IDH1-mutant tumors [73]. These findings suggest that the IDH1 mutation leads to the inhibition of autophagic flux, resulting in the promotion of cell death. Thus, attenuating autophagic activation may contribute to a better response to TMZ in IDH1 mutant tumors.

**Plant-derived compounds**
To enhance the benefit of TMZ in the treatment of aggressive glioblastomas, effective combination strategies that sensitize glioblastoma cells to TMZ are important to prevent the recurrence of these tumors. In this regard, natural products, such as flavonoids, have received considerable attention because of their lower amount of side effects and effectively inhibition of autophagy-mediated the pro-survival roles [74]. Chrysin, the most active ingredient of pine needle extract, markedly inhibited TMZ-induced autophagy and induced apoptosis, indicating that chrysin may serve as a potential anticancer agent against glioblastomas [75]. Resveratrol (Rsv), a natural, purified polyphenolic compound, has additive toxicity with TMZ in several glioma cell lines in vitro [76] and in vivo [42]. Lin Cj et al. found that Rsv acts synergistically with TMZ in apoptosis, which is accompanied by a decrease in TMZ-induced cytoprotective autophagy. The co-administration of Rsv and TMZ reduced tumor volumes by suppressing ROS/ERK-mediated autophagy and subsequently inducing apoptosis in a mouse xenograft study [42]. Autophagy inducer sulforaphane (SFN), a isothiocyanate derived from cruciferous plants [77], could remarkably suppress cell growth and enhance cell death in TMZ-resistant glioblastoma cells and xenografts [78]. Given autophagy inhibition could enhance SFN-induced apoptosis in the breast cancer [79], prostate cancer [80], etc., combination autophagy inhibitor and SFN might be a synergistically promising strategy for the TMZ treatment on GBM. Additionally, due to protective autophagy mechanism both in vitro and in vivo, the synergy between therapeutic agent curcumin and TMZ was not achieved. Autophagy inhibition could improve the efficacy of curcumin/TMZ combination therapy, providing novel opportunities to improve brain tumor treatment [81].

As the different physicochemical property of plant-derived extracts and stimulation intensity on cells, other progresses have shown that some compounds, like the Cannabis sativa (CS), could enhance the TMZ sensitivity by inducing the autophagic cell death. Even though most people are familiar with the palliative effects of the primary psychoactive constituent of CS, non-psychoactive cannabinoids can inhibit tumor cell viability, invasion, metastasis, and angiogenesis of cancer cells, such as glioma cell lines, which are closely related to autophagy and apoptotic-mediated cancer cell death [82, 83]. Studies have found that Δ9-tetrahydrocannabinol (THC), the main active component of CS, can induce autophagy-mediated cell death through the stimulation of endoplasmic reticulum stress or the midkine/ALK (anaplastic lymphoma kinase) axis and can further sensitize therapy-resistant tumors to antitumor action [84, 85]. Torres S et al. found that the combined administration of THC and TMZ exerts a strong anti-tumor action in glioma xenografts and TMZ-resistant xenografts with MGMT-positive T98G cells, an effect that relies, at least in part, on the stimulation of autophagy-associated cell death in tumor cells. However, the inhibition of the autophagic process using the class III PI3K inhibitor 3-methyladenine (3-MA)
could prevent TMZ and THC-induced cell death [86]. Alternative attractive compound to sensitize the cells to TMZ is a steroidal lactone derived from several genera of the Solanaceae plant family, Withaferin A (WA). Combination treatment with WA and TMZ resulted in resensitization of MGMT mediated TMZ-resistance by Akt/mTOR pathway inhibitory modulation [87], which probably enhance the autophagic cell death in PTEN-null U87 glioma cells [88].

**Autophagy-associated cell death**

In the treatment of glioblastomas, chemotherapeutic drugs, including arsenic trioxide and TMZ [89], can trigger autophagy-associated cell death and further improve their therapeutic effects. Autophagy inhibition may produce controversial cellular outcomes, including cytoprotection as alluded above and autophagy-associated cell death. Autophagy-associated cell death exerts its effect primary through the overactivity of autophagy, by which the degradation of cytoplasmic content proceeds to completion. Using siRNA against the Beclin1 or ATG7 genes totally prevents the decrease in viability after radiation/TMZ treatments in T98G and U373 glioblastoma cell lines [23]. In addition, autophagy-mediated apoptosis stimulating agents, such as Δ9-tetrahydrocannabinol [86] and oncolytic adenovirus CRAd-Surivin-pk7 [90], combined with TMZ strongly reduce the growth of glioma xenografts, suggesting that the combined administration of TMZ and autophagy inhibitors could be therapeutically exploited for the management of GBM. These results enforce the concept that autophagy-associated cell death might constitute a possible adjuvant therapeutic strategy to enhance conventional GBM treatments (Tables 2 and 4).

**Kinase inhibitors**

Though some kinases inhibitors above mentioned have been proved to increase the cytotoxicity of TMZ by inhibiting the cell autophagy, recent studies have indicated that other kinase inhibitors, like the tyrosine kinase inhibitors (TKI), could cause the remarkable autphagic cell death [91], and resulted in a significant reduction in glioma tumor growth [92]. Milano V’s group found that Dasatinib (BMS-354825), an orally bioavailable tyrosine kinase inhibitor, could lead to a significant increase in the sensitivity to TMZ therapy via generating cell cycle disruption and autophagic cell death [93]. Furthermore, the cell surface receptor, epidermal growth factor receptor tyrosine kinase (EGFR-TK) is highly amplified, mutated, and overexpressed in human malignant gliomas [94]. EGFR signaling could induce the phosphorylation of pro-survival STAT3, ERK1/2 and Akt, which contributes significantly to GBM cell proliferation [95]. Thus, therapeutic strategies to inhibit EGFR kinase activity represent an avenue of profound beneficial effects for gliomas. The combined treatment of nimotuzumab (monoclonal antibody against EGFR) and rapamycin effectively enhances glioma cell death in TMZ-resistant glioma cells [31]. The over-expression of miR-340 suppressed several oncogenes, including EGFR, and further dramatically inhibited glioma cell proliferation, induced cell-cycle arrest and apoptosis, and promoted autophagy [96]. EGFR interference using siRNA results in an increase of TMZ cytotoxicity in T98G TMZ-resistant cells, which was through activation of a pro-death autophagy process [97].

The aberrant PI3K/Akt/mTOR pathway has been shown to contribute to the resistant phenotype of gliomas [36, 98]. Therefore, the PI3K/Akt/mTOR pathway is regarded as an important amenable pathway for pharmacological interventions in gliomas. In radioresistant glioma cells, treatment with the mTOR inhibitors rapamycin and PP242 can enhance radiosensitivity by potently and persistently activating the autophagic flux [99]. After combined radiotherapy and TMZ treatments, rapamycin-mediated autophagy is able to promote malignant glioma cell death [23]. Another group also found that PI103, a dual inhibitor of PI3K and mTOR, could increase autophagy and further increase the cytotoxicity of radiation and TMZ [100]. However, it was note worthy that, as opposed to the previous findings, treatment with rapamycin alone did not discernibly potentiate the radiosensitizing effect of TMZ in both U251 and T98G cells [100]. These results suggest that more careful studies are needed to determine optimal treatment combinations of TMZ and mTOR inhibitors.

Sphingolipids are structural and functional components of biological membranes, which benefit the maintenance of membrane structure and fluidity. They are also implicated in bio-effector roles in cancer pathogenesis. The roles of bioactive sphingolipids, specifically sphingosine kinase 1 (SK1) and 2 (SK2) and their product—sphingosine 1-phosphate (S1P), have been shown to regulate the cancer cell proliferation, survival, and treatment responses. Modulating the metabolism of bioactive sphingolipids has been shown to be a potentially important target in treating malignancies [101, 102]. Particularly, because sphingosine kinases (SK1 and SK2), serving as the oncogenic enzymes, have been found to induce transforming phenotype in many tumors, including glioblastomas [37, 103], inhibition of SK may become a promising anticancer strategies [104]. Noack J et al. found that the combination of TMZ and sphingosine kinases inhibitors (SKIs) resulted in an increase autophagic flux and further induced cell death in GBM cell lines. This role of autophagy-associated cell death in the combination of SKI and TMZ treatment was demonstrated by the decrease in cell death after specific and efficient the siRNA-mediated knockdown of Beclin1 [105].
Histone deacetylases inhibitors

Histone deacetylases (HDACs) constitute a family of enzymes that play important roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation and apoptosis of cancer cells, including glioblastomas [106]. Recently, strategies to enhance tumor cytotoxicity and radiosensitivity have started to focus on HDACs. Many HDAC inhibitors have been demonstrated to enhance the cytotoxicity and therapy sensitivity of human glioma cell lines [107]. Among these HDAC inhibitors, 2-propylpentanoic acid (VPA) is one of the most interesting. VPA is a short-chain fatty acid that belongs to the HDAC inhibitor family. A combination of VPA and TMZ has a significantly enhanced antitumor effect in TMZ-resistant malignant glioma cells. This enhanced antitumor effect correlates with enhanced apoptotic and autophagic cell death [108]. Chen’s group also found if combined with VPA for 96 hours, the sensitivity of glioma cells to TMZ was significantly increased. The combination treatment of TMZ and VPA results in a significant cell cycle block and increased apoptotic rates as well as autophagy rates in T98G and SF295 cell lines [109].

Bcl2 family inhibitors

As mentioned earlier, antiapoptotic Bcl-2 family members, such as Bcl2L12, suppress both apoptosis and autophagy, and they are of major importance for therapy
resistance of malignant gliomas [110]. The deregulation of Bcl2 family proteins mostly contributes to apoptosis evasion, suggesting that the inhibition of Bcl2 proteins is one of the most promising new approaches to targeted cancer therapy [111]. The Bcl2 inhibitor ABT-737 could counteract the anti-apoptotic role of Bcl2L12 and sensitize drug response of GBM cells to TMZ [110]. In addition, the pan-Bcl2 inhibitor (-)-gossypol efficiently potentiates caspase-independent autophagic cell death in apoptosis-resistant malignant glioma cells, and it further augments the action of TMZ. The extent of this cell death could be strongly diminished by the lentiviral knockdown of Beclin1 and ATG5 [112].

**Nuclear factor E2-related factor 2 inhibition**

Nuclear factor E2-related factor 2 (Nrf2), a pivotal transcriptional factor of cellular responses to oxidative stress, is observed to function remarkably in glioblastoma pathobiology. Nrf2 activation contributes to the tumorigenesis of autophagy-deficient cells [113]. In addition, a significant negative correlation has been found between Nrf2 expression and the outcome for GBM patients [114]. Recent studies have reported that development of chemoresistance is associated with the constitutive activation of the Nrf2-mediated signaling pathway in many types of cancer cells, including gliomas [115]. Chrysin, a potent Nrf2 inhibitor, could effectively reverse the resistance of an anticancer drug by down-regulating the PI3K/Akt and ERK pathways [116]. The knockdown of Nrf2 by siRNA enhances autophagy induced by TMZ and decreases the viability of U251 cells [117]. These findings suggest that the combination of TMZ and the inhibition of Nrf2 may point to a novel therapeutic opportunity for GBM to enhance the antitumor effects of TMZ.

**Oncolytic adenoviruses**

The potential use of adenoviruses in therapy against cancer has evoked a rapidly moving field of research. Emerging evidence indicates that as a cancer drug, oncolytic adenoviruses can induce autophagic cell death in glioma cancer cells [118]. The use of autophagy inducers, such as rapamycin, can enhance the oncolytic potency of recombinant adenoviruses. Furthermore, studies have demonstrated the capability of adenoviruses to inhibit the expression of the DNA repair enzyme MGMT and to chemosensitize glioma cells to TMZ [119]. As oncolytic adenoviruses show promising safety and efficacy, the combination of oncolytic adenoviruses with TMZ could increase tumor cell autophagy and elicit antitumor immune responses, resulting in disease control in 67 % of chemotherapy refractory cancer patients [120]. Ulasov IV et al. also found that pretreatment with TMZ, followed by treatment with oncolytic adenovirus CRAdSurivin-pk7, exhibits an additive cytotoxicity effect in vitro and in vivo, which is associated with increased autophagy-associated cell death and a therapeutic additive effect in the survival of mice bearing intracranial glioma xenografts [90].

**Pertussis toxin**

Pertussis toxin (PTx), an exotoxin produced by *Bordetella pertussis*, regulates the activation induced by autophagic process in cancer cells [121]. A recent study indicated that PTx has the potential to be useful as an adjunct to TMZ chemotherapy on gliomas. Concomitant treatment with TMZ and PTx can elicit autophagic cell death *in vitr*o and increase survival in the RG2 glioma model [122].

**Conclusions**

Resistance to TMZ chemotherapy is a major obstacle to the success of glioma therapy. The roles of autophagy regulation, which cause multiple impacts on chemosensitivity, are still highly perplexing in glioma treatment. Clearly, the regulation of autophagy corresponding to TMZ therapy and the resulting downstream effects are complex and are very likely to be in a cell type-specific manner. The competence of a cell to survive or die is theoretically proportional to the doses and duration of TMZ treatment, the DNA-damage repair capacity of the cells, the proliferation level, and the effectiveness of activating DNA repair proteins including ATM kinases. How can the autophagy act as the pro-survival or pro-death roles, and how are the decisions made? Hypothetical models predict that with the low doses and short-term TMZ treatment, autophagy is a survival mechanism, whereas upon the persistent TMZ treatment, autophagy becomes a process that is out of control and induce the cell death. With this context, the treatment thresholds have an import role. These pro-death and pro-survival pathways, and how they interact, are needed to be discussed more in the future.

Although the controversy about the prosurvival or anticancer effect of autophagy is still heated, the data in clinical trials seem to support the cytoprotective role of autophagy inhibitors, such as CQ and its analogs, preceding treatment with TMZ. However, whether other different autophagy inhibitors, such as bafilomycin A1, monensin, 3-MA, pyrvinium and wortmannin, which block the autophagic process at different stages, have the same pharmacological features as CQ are still unknown. At the present, it is not completely clear how autophagy influences cells, especially in TMZ resistant tumors. Moreover, it remains unclear how autophagy participates in the unique mechanical properties of microenvironments (e.g., hypoxia and acidity) under TMZ exposure.
Further investigation of these issues may help to identify more combination strategies to enhance the benefits of TMZ chemosensitivity and chemoprotection in the treatment of aggressive glioblastomas.

Abbreviations
GBM: glioblastoma multiforme; TMZ: temozolomide; ROS: reactive oxygen species; MGMT: N7-methylguanine-DNA methyltransferase; ATM: Ataxia telangiectasia mutated; ERK: extracellular signal-regulated kinase; AMPK: adenosine monophosphate-activated protein kinase; eEF-2: eukaryotic elongation factor-2; VAMP8: vesicle-associated membrane protein 8; CQ: Chloroquine; mTOR: the mechanistic target of rapamycin (serine/threonine kinase); SK: spheroid kinase inhibitors; EGFR: epidermal growth factor receptor; Nrf2: nuclear factor E2-related factor 2.

Competing interests
The authors declare that there are no conflicts of interests.

Authors’ contributions
YLX and ZCG were the main authors of the manuscript; ZIX revised the most of reviewers’ comments and completed the last format of the manuscript; SD contributed to bibliography collection as well as figures and tables design and format; LQG revised the manuscript for important intellectual content; LQ corrected the language form; YLY and ZCG was responsible for the manuscript writing. All authors read and approved the final manuscript.

Acknowledgement
This work is supported by the National Natural Science Foundation of China (No. 81572946), the Changsha Science and Technology Project (No. k1508024-31), and the Clinical and Rehabilitation Research Foundation of Xiangya Hospital - Beidewimming.

Author details
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China. 2Institute of Hospital Pharmacy, Central South University, Changsha 410008, China. 3Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China. 4Center for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South University, Changsha 410008, China.

Received: 2 December 2015 Accepted: 28 January 2016 Published online: 02 February 2016

References
1. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319–31.
2. Kintely JP, Baehring JM. A silver lining on the horizon for glioblastoma. Lancet Oncol. 2009;10:434–45.
3. Nanegruengsun D, Onchan W, Chattipakorn N, Chattipakorn SC. Current evidence of temozolomide and bevacizumab in treatment of gliomas. Neurol Res. 2015;37:167–83.
4. Messoudi K, Clavelier A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of clavatoma to temozolomide. Drug Discov Today. 2015;20:899–905.
5. Sunt SD, Prabhu RS, Burri SH, Atkins TG, Asher AL. Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol. 2015;17 Suppl 2:S19–I23.
6. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.
7. Paglin S, Hollister T, Debeyne T, Hackett N, McMahill M, Spickas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439–44.
8. Fulda S, Kogel D. Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene. 2015;34:1505–13.
9. Galluzzi L, Morelli E, Vicenzo JM, Kepo O, Joza N, Tajeddine N, et al. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans. 2008;36:785–90.
10. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12 Suppl 2:S109–18.
11. Kang C, Avery L. To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation. Autophagy. 2008;4:82–4.
12. Guo XL, Li D, Hu F, Song JR, Zhang SS, Deng WL, et al. Targeting autophagy potentiates chemotheraphy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett. 2012;320:171–9.
13. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 2007;13:2721–9.
14. Han W, Sun J, Feng L, Wang K, Li D, Pan Q, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One. 2011;6:e28491.
15. Josset E, Buckel H, Noel G, Biochhoff P. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res. 2013;33:1845–51.
16. Tai WT, Shiu CW, Chen HL, Liu CY, Lin CS, Cheng AL, et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death production by sorafinib and SC-59 in hepatocarcinoma cells. Cell Death Dis. 2013;4:e485.
17. Kondo Y, Kondo S, Autophagy and cancer therapy. Autophagy. 2006;2:85–90.
18. Li S, Jiang T, Li G, Wang Z. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res. 2008;30:567–70.
19. Carma A, Carvalheiro H, Crespo I, Nunes I, Lopes WC. Effect of temozolomide on the U-118 glioma cell line. Oncol Lett. 2011;2:165–70.
20. Kanazawa T, Germano IM, Kornata T, Ro H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11:448–57.
21. Filippp-Chiela EC, Silva MM B, et al. Thome MP, Lenz G. Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. Autophagy. 2015;11:1099–113.
22. Gao S, Yang XI, Zhang WG, Yi WY, Pan Q. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl). 2009;122:1260–6.
23. Palumbo S, Piroli T, Lini P, Cevenini G, Calderaro F, Toscano M, et al. Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments. J Cell Biochem. 2012;113:2308–18.
24. Zhang J, Stevens MF, Badshah TD. Temozolomide mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102–14.
25. Kanazawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg. 2003;99:1047–52.
26. Anai S, Hide T, Takezaki T, Kuroda J, Shinjoh N, Makino K, et al. Antitumor effect of fibrin glue containing temozolomide against malignant glioma. Cancer Sci. 2014;105:583–91.
27. Jiang G, Li LT, Xin Y, Zhang L, Liu YQ, Zheng JN. Strategies to improve the efficacy of fibrin glue containing temozolomide against malignant glioma. Cancer. 2013;98:1323–9.
28. Anai S, Hide T, Takezaki T, Kuroda J, Shinjoh N, Makino K, et al. Antitumor effect of fibrin glue containing temozolomide against malignant glioma. Cancer Sci. 2014;105:583–91.
29. Filipp-Chiela EC, Silva MM B, et al. Thome MP, Lenz G. Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. Autophagy. 2015;11:1099–113.
30. Gao S, Yang XI, Zhang WG, Yi WY, Pan Q. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl). 2009;122:1260–6.
31. Palumbo S, Piroli T, Lini P, Cevenini G, Calderaro F, Toscano M, et al. Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments. J Cell Biochem. 2012;113:2308–18.
32. Zhang J, Stevens MF, Badshah TD. Temozolomide mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102–14.
33. Kanazawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg. 2003;99:1047–52.
34. Anai S, Hide T, Takezaki T, Kuroda J, Shinjoh N, Makino K, et al. Antitumor effect of fibrin glue containing temozolomide against malignant glioma. Cancer Sci. 2014;105:583–91.
35. Jiang G, Li LT, Xin Y, Zhang L, Liu YQ, Zheng JN. Strategies to improve the efficacy of fibrin glue containing temozolomide against malignant glioma. Cancer Sci. 2014;105:583–91.
36. Anai S, Hide T, Takezaki T, Kuroda J, Shinjoh N, Makino K, et al. Antitumor effect of fibrin glue containing temozolomide against malignant glioma. Cancer Sci. 2014;105:583–91.
54. Zou Y, Wang Q, Wang W. Mutational profiling of kinases in glioblastoma. BMC Cancer. 2014;14:718.

55. Motta C, D’Angel F, Scala M, Saratino C, Barbagallo D, Naletova I, et al. PI3-K inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells. Eur J Pharmacol. 2015;761:55–64.

56. Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep. 2015;35.

57. Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different brain tumors. J Neurol. 2014;261:193–211.

58. Wang Z, Yuan H, Sun C, Xu L, Chen Y, Zhu Q, et al. GATA2 promotes glioma growth progression through ERFR/ERK/Erk-1 pathway. Med Oncol. 2015;32:87.

59. Costa B, Bendinelli S, Gabeloni P, Da Pozzo E, Daniele S, Scatena F, et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One. 2013;8, e72281.

60. Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, et al. The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett. 2015;360:195–204.

61. Liu X, Wang L, Chen J, Ling Q, Wang H, Li S, et al. Estrogen receptor beta agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. Mol Med Rep. 2015;11:1516–22.

62. Riccietti E, Giussani P, Di Wito C, Condottimi G, Trigalli C, Caroli M, et al. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. PLoS One. 2013,8, e68229.

63. Pointer KB, Clark PA, Zomiak M, Alrfaei BM, Kuo JS. Glioblastoma cancer stem cells Biomarker and therapeutic approaches. Neurochem Int. 2014;71:1–7.

64. Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, et al. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 2013,8, e68397.

65. Knishnik AV, Roos WP, Nikolaov T, Quirons S, Tomaszowski KH, Christmann M, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One. 2013,8, e55665.

66. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. A phase III trial of hydroxychloroquine in conjunction with radiation therapy and concurrent temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10:1359–68.

67. Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52:377–91.

68. Aghiottiti S, Burrell K, Buczkowicz P, Remke M, Caroli M, et al. ATP regulates 3-methyluridine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014;4:1198–213.

69. Takala-Harrison S, Lafer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015;1342:66–72.

70. Al-Bari MA. Choroideremia analogues in drug discovery: new directions of uses, mechanisms of action and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–21.

71. Li C, Liu Y, Liu H, Zhang W, Shen C, Cho K, et al. Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cell Physiol Biochem. 2015;35:1303–16.

72. Hori YS, Hosoda R, Akiyama Y, Sebori R, Wainbuchi M, Mikami T, et al. Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. J Neurooncol. 2015;122:11–20.

73. Golden EB, Cho HY, Jahansian A, Hofman FM, Louie SG, Schonthal AH, et al. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg Focus. 2014;37, E2.

74. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38, E2.

75. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosci Focus. 2003;1:14–8.

76. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:337–43.

77. Bleeker PE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, et al. Mutational profiling of kinetics in glioblastoma. BMC Cancer. 2014;14:718.

78. Shihol Y, Ziv Y. The ATP protein kinase regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14:197–210.

79. Zou Y, Wang Q, Wang W. Mutl homolog 1 contributes to temozolomide-induced autophagy via axatia- translignehia mutatia in glioma. Mol Med Rep. 2015;11:4591–6.

80. Zou Y, Wang Q, Li B, Xie B, Wang W. Temozolomide induces autophagy via ATM/WAKU1 pathways in glioma. Mol Med Rep. 2014;10:411–6.

81. Nadkarni A, Shirvastav M, Mladek AC, Schwingler PM, Grogen PT, Chen J, et al. ATM regulates INK19 increases the TMZ response in inherently TMZ sensitive GBM cells. J Neurooncol. 2012;110:349–57.

82. Burotto M, Chioo VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120:3446–56.

83. Wang Z, Yuan H, Sun C, Xu L, Chen Y, Zhu Q, et al. GATA2 promotes glioma progression through EGRF/ERK/Erk-1 pathway. Med Oncol. 2015;32:87.
81. Zacchello F, Pizzocaro G, Manoukian V, et al. Autophagy induction improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015;358:220–31.

82. Malur A, Kooistra T. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J Neuroimmunol. 2015;255–62.

83. Scott KA, Dalgleish AG, Liu WM. The combination of cannabinoid and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 2014;13:2955–67.

84. Salazar M, Carracedo A, Salanueva U, Hernandez-Tiedra S, Lorente M, Eiga A, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2008;119:1359–72.

85. Lorente M, Torres S, Salazar M, Carracedo A, Hernandez-Tiedra S, Rodriguez-Fornes F, et al. Stimulation of AK8 by the growth factor midkine enders glioma cells resistant to autophagy-mediated cell death. Autophagy. 2011;7:1071–83.

86. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10:90–103.

87. Goggin PT, Sarkaria JN, Timmermann BN, Cohen MS. Oxidative cytotoxic agent withafarin A sensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibition. Invest New Drugs. 2014;32:604–17.

88. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antiproliferative effect of chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013;34:2080–9.

89. Zhang J, Hummersone M, Matthews CS, Stevens MF, Bradshaw TD. N3-substituted temozolomide analogs overcome methyl glycinidone-DA methyletherinase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Oncology. 2013;88:28–48.

90. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Oncotarget. 2015;6:2257–70.

91. Palumbo S, Tini P, Toscano M, Allavena G, Angeletti F, Manai F, et al. A cotherapy with a Bcl-2 inhibitor and a BH3-like domain in regaining apoptotic and TMZ2-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma. Int J Oncol. 2015;46:1304–16.

92. Scarfo L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155:36–9.

93. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, et al. The pan-Bcl-2 inhibitor (#)gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res. 2010;8:1002–16.

94. Santeramo N, Bertoni F, Abbracchio MP, et al. Oncogenic functions of the transcription factor NF2. Free Radic Biol Med. 2013;65:750–64.

95. J X, Wang H, Zhu J, Tang Y, Zhou Y, Zhu L, et al. Correlation of NF2 and HIF-1alpha in glioblastoma and their relationships to clinicopathologic features and survival. Neurol Res. 2013;35:1044–50.

96. Sukumari-Ramesh S, Prasad N, Alleyne CH, Vender JR, Dhodapkar KM. Overexpression of Nr2f2 attenuates CARMUSTINE-induced cytotoxicity in U87MG human glioma cells. BMC Cancer. 2015;15:118.

97. Gao AM, Ke ZP, Shi F, Sun GC, Chen H. Chrysin enhances sensitivity of BEL-201 human glioma cell lines to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact. 2013;206:100–8.

98. Zhou Y, Wang HD, Zhu L, Cong ZX, Li NJ, Ji X, et al. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol Rep. 2013;29:394–400.

99. Tazawa H, Kawagawa H, Fujitawa T. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Acta Med Okayama. 2013;67:333–42.

100. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther. 2010;12:50–6.

101. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, et al. Combined EGFR and autophagy modulation impairs cell migration and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis. 2014;14:e1245.